Eli Lilly and Company News - August 7, 2026

Lilly's Next-Gen Obesity Drug Gets a Head Start — But Can Retatrutide Justify the Stock's Bounce Before FDA Even Weighs In?
LLY

Lilly's Next-Gen Obesity Drug Gets a Head Start — But Can Retatrutide Justify the Stock's Bounce Before FDA Even Weighs In?

Shares of Eli Lilly surged 5.3% to $1,175 in pre-market trading Thursday, snapping a week-long slide, after the company formalized an expanded early-access...
LLY

Lilly's Next-Gen Obesity Drug Gets a Head Start — But Can Retatrutide Justify the Stock's Bounce Before FDA Even Weighs In?

Shares of Eli Lilly surged 5.3% to $1,175 in pre-market trading Thursday, snapping a week-long slide, after the company formalized an expanded early-access...